Edgar Filing: Sarepta Therapeutics, Inc. - Form 4

Sarepta Ther Form 4 August 27, 2	apeutics, Inc. 012									
FORM	1 /								PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or						Expires: Estimated burden hou response	irs per			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type F	Responses)									
1. Name and A HODGMAN	Symbol	2. Issuer Name and Ticker or Trading Symbol Sarepta Therapeutics, Inc. [SRPT]				5. Relationship of Reporting Person(s) to Issuer				
		•	•		[SKI	-1]	(Chee	ck all applicabl	e)	
(Month			B. Date of Earliest TransactionMonth/Day/Year)08/23/2012				XDirector10% Owner Officer (give titleOther (specify below)below)			
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person						
BOTHELL, WA 98021 Form filed by More than One Reporting Person										
(City)	(State) (Zip)	Tabl	e I - Non-D	erivative S	Securi	ties Ac	quired, Disposed o	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	aı		3. Transactio Code (Instr. 8)	4. Securit onAcquired Disposed	ties (A) of of (D 4 and (A) or	or))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	-	
Common Stock	08/23/2012		А	833 <u>(1)</u>	А	\$0	3,333 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day,	ate	7. Title and A Underlying S (Instr. 3 and	Securities	8. I Dei Sec (Ini
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 10.08	08/23/2012		А	5,000	(3)	08/23/2022	Common Stock	5,000	

Edgar Filing: Sarepta Therapeutics, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
HODGMAN JOHN 3450 MONTE VILLA PARKWAY, SUITE 101 BOTHELL, WA 98021	Х				
Signatures					

/s/ John	
Hodgman	08/27/2012
<u>**</u> Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant of restricted stock, which shall vest in full on the earlier of (i) the anniversary date of the grant and (ii) the date of the 2013 annual meeting of shareholders.
- (2) The number of shares reported reflects the 1-for-6 reverse stock split of the common stock of the Issuer effective as of July 11, 2012.
- (3) Option shall vest in full on the earlier of (i) the anniversary date of the grant and (ii) the date of the 2013 annual meeting of shareholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.